Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). Like sermorelin, it stimulates the pituitary gland to increase the body’s natural production of growth hormone. However, tesamorelin is a more stabilized and longer-acting version of the molecule, designed for more sustained physiologic activity.
Tesamorelin is FDA-approved under the brand name Egrifta® for one specific indication: reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
Outside of that FDA-approved use, tesamorelin may sometimes be prescribed off-label by licensed medical providers as part of a broader metabolic optimization, body composition, or longevity-focused treatment plan when clinically appropriate.
At Alpha Hormones® in Pasadena, tesamorelin is not approached as a casual wellness product or internet peptide trend. It is a prescription therapy that belongs in a proper medical discussion—one that evaluates your hormones, metabolic health, body composition, lifestyle factors, and long-term goals before treatment decisions are made.
Patients from Pasadena, Los Angeles, Glendale, Arcadia, and surrounding Southern California areas often explore tesamorelin therapy for concerns related to:
Ready to learn whether tesamorelin may fit your goals?
Research on tesamorelin has primarily focused on visceral adipose tissue—the metabolically active fat surrounding the organs that contributes to cardiovascular and metabolic risk.
The most well-documented effect of tesamorelin, particularly in patients with HIV-associated lipodystrophy where it was originally studied.
Tesamorelin may increase IGF-1 levels through stimulation of the body’s own pituitary growth hormone pathway. IGF-1 is routinely monitored as part of treatment safety and optimization.
Some studies have demonstrated favorable effects on triglycerides and other metabolic lipid markers.
Emerging research has evaluated possible effects on hepatic fat content and broader metabolic function in select populations.
As with other GHRH-based peptides, some patients report subjective improvements in sleep quality, recovery, energy, and overall well-being over time.
At Alpha Hormones®, we focus on:
Effects outside the FDA-approved indication remain less established and vary significantly between individuals. Tesamorelin is not intended to replace foundational lifestyle, metabolic, or hormone optimization strategies.
Tesamorelin is administered as a daily subcutaneous injection, most commonly in the evening to align with natural physiologic growth hormone pulses.
At Alpha Hormones®, treatment follows a physician-guided, data-driven approach focused on safety, monitoring, and individualized care.
Our CLIA-certified in-house lab allows many patients to receive same-day metabolic and hormone testing.
Testing may include:
Visceral fat is not the same as subcutaneous fat. Accurate measurement and monitoring matter.
Tesamorelin may not be appropriate in patients with:
Pregnancy or specific endocrine conditions
There is no reason to continue therapy longer than the clinical picture supports.
Because tesamorelin can influence insulin sensitivity and metabolic pathways, ongoing follow-up is important.
Tesamorelin is often incorporated alongside:
At Alpha Hormones®, we treat the entire metabolic and hormonal system—not just one lab value or symptom.
Medication is sourced through licensed U.S. pharmacies. Prescribing decisions are made by licensed medical providers based on a patient’s complete clinical picture—not through automated online questionnaires.
Tesamorelin may be worth discussing with a provider if you:
Patients exploring tesamorelin often also consider:
A consultation helps determine which strategy—or combination of strategies—best fits your biology and goals.
When clinically appropriate, tesamorelin is prescribed through licensed U.S. pharmacies only.
At Alpha Hormones®, we do not support:
Injectable peptides from unregulated sources may carry significant risks, including:
Your safety and long-term outcomes come first.
Tesamorelin (Egrifta®) is FDA-approved specifically for reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
Any use outside that indication is considered off-label and requires individualized clinical judgment by a licensed medical provider following a comprehensive evaluation.
Information on this page is educational and does not replace medical advice or physician evaluation. Individual results vary, and no specific outcome is guaranteed.
Yes—but for a specific indication. Tesamorelin is FDA-approved as Egrifta® for reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
Any other use is considered off-label and requires medical evaluation and clinical judgment by a licensed provider.
Both are GHRH-based peptides, but tesamorelin is a more stabilized and longer-acting analog designed for sustained physiologic activity.
Tesamorelin also has a dedicated FDA-approved indication, whereas sermorelin is typically prescribed off-label through compounding pharmacies.
A consultation helps determine which, if either, may fit your goals and metabolic profile.
Tesamorelin is not primarily prescribed as a general weight-loss medication. Its most studied effects involve visceral abdominal fat and metabolic body composition.
For broader weight management goals, therapies such as semaglutide or tirzepatide may sometimes be more appropriate depending on the individual.
Tesamorelin is administered as a daily subcutaneous injection, most commonly in the evening to align with natural growth hormone secretion patterns.
Your provider will review:
before treatment begins.
Possible side effects may include:
Because tesamorelin may influence glucose metabolism, blood sugar and insulin sensitivity are monitored during treatment.
More serious risks—including concerns involving active malignancy or pituitary abnormalities—are screened for prior to therapy.
In some cases, yes, when clinically appropriate.
Visceral fat, insulin resistance, low testosterone, thyroid dysfunction, poor recovery, and metabolic slowdown are often interconnected. Coordinated care is generally more effective than stacking therapies without a structured plan.
Depending on the patient, tesamorelin may be combined with:
Duration varies depending on:
Some patients use tesamorelin for a defined treatment course, while others may remain on therapy longer under ongoing supervision.
Stopping treatment should always be a medical decision guided by your provider.
Insurance coverage may sometimes be available for the FDA-approved HIV lipodystrophy indication.
For off-label body composition or longevity-focused use, coverage is typically limited.
Our team can assist with:
In many cases, yes. HSA and FSA cards are commonly accepted for:
Eligibility ultimately depends on your individual plan administrator.
Alpha Hormones® provides a physician-guided, comprehensive approach to:
Patients choose us for:
We believe peptide therapy should be medically supervised, individualized, and evidence-informed.
If visceral fat, body composition, metabolic optimization, or longevity-focused peptide therapy is on your mind, the next step is a real medical conversation—not an online form that bypasses proper evaluation.
At Alpha Hormones® in Pasadena, our licensed providers evaluate:
to determine whether tesamorelin—or another treatment strategy—best fits your needs.
Ready to explore tesamorelin therapy?
Tesamorelin (Egrifta®) is FDA-approved for a specific indication and is prescribed only after evaluation by a licensed medical provider.
This content is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Off-label prescribing requires individualized clinical judgment by a qualified provider.
Individual results vary and are never guaranteed. Always consult with a licensed healthcare provider before starting, adjusting, or stopping any treatment.